AngioDynamics, Inc.·Healthcare

The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.

AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.

AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 third-quarter results that management described as "strong across the board," highlighted by faster growth in its MedTech segment and improved adjusted EBITDA. The company also raised its full-year outlook for net sales and adjusted EBITDA for the third consecutive quarter, citing continued execution across its core platforms. Quarterly results show

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Healthcare
Medical - Instruments & Supplies
748
2004-06-01
0.43